Nephron Pharmaceuticals - About the company
Nephron Pharmaceuticals is a late stage company based in Florida (Puerto Rico), founded in 1937 by Lou Kennedy. It operates as a Manufacturer of sterile pharmaceutical products and provider of contract manufacturing and 503B outsourcing services. Nephron Pharmaceuticals has raised $625M in funding from PNC and Blackrockbkcc.
Company Details
Manufacturer of sterile pharmaceutical products and provider of contract manufacturing and 503B outsourcing services. It specializes in the production of generic respiratory medications and offers sterile, pre-filled medications to address drug shortages. The company's services encompass the entire manufacturing process, from development to packaging, within state-of-the-art facilities. A focus on efficiency, purity, and efficacy ensures high-quality products for healthcare providers. The company also supports community initiatives and invests in educational programs related to pharmacy and healthcare.
- Website
- nephronpharm.com
- Social
- Registered Address
- West Columbia, South Carolina
Key Metrics
Founded Year
1937
Location
Florida, Puerto Rico
Stage
Late Stage
Total Funding
$625M in 5 rounds
Latest Funding Round
Employee Count
865 as on Aug 31, 2026
Legal entities associated with Nephron Pharmaceuticals
Nephron Pharmaceuticals is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Nephron Pharmaceuticals Corp CIN: 1617435 , United States, Active | $1 - $1M (As on Aug 20, 2014) | - | - | |
NEPHRON PHARMACEUTICALS CORPORAT CIN: 931065757 , United States, Active | Dec 31, 1999 | - | 798 (As on Dec 31, 2024) | - |
Sign up to download Nephron Pharmaceuticals' company profile
Nephron Pharmaceuticals's funding and investors
Nephron Pharmaceuticals has raised a total funding of $625M over 5 rounds. Its first funding round was on Aug 2014. Its latest funding round was a Conventional Debt round on Jan 10, 2025 for $*****. 1 investor participated in its latest round. Nephron Pharmaceuticals has 5 institutional investors.
Here is the list of recent funding rounds of Nephron Pharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 10, 2025 | 1418742 | Conventional Debt | 7611768 | 5224635 | 9173429 | 4377890 |
Sep 15, 2023 | 5198373 | PE | 6419974 | 5031295 | 5013009 | 5855518 |
Aug 2017 | 7902168 | Conventional Debt | 1215920 | 2370243 | 9318112 |
Access funding benchmarks and valuations. Sign up today!View details of Nephron Pharmaceuticals's funding rounds and investors
Nephron Pharmaceuticals' founders and board of directors
Founder? Claim ProfileThe founders of Nephron Pharmaceuticals is Lou Kennedy.
Here are the details of Nephron Pharmaceuticals' key team members:
- Lou Kennedy: Owner of Nephron Pharmaceuticals. Contact Info: 1 email address
View details of Nephron Pharmaceuticals's Founder profiles and Board Members
Nephron Pharmaceuticals' employee count trend
Nephron Pharmaceuticals has 865 employees as of Aug 26. Here is Nephron Pharmaceuticals's employee count trend over the years:
Uncover Nephron Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nephron Pharmaceuticals's Investments and acquisitions
Nephron Pharmaceuticals has made no investments or acquisitions yet.
Reports related to Nephron Pharmaceuticals
Here is the latest report on Nephron Pharmaceuticals's sector:
News related to Nephron Pharmaceuticals
Filter this listMedia has covered Nephron Pharmaceuticals for 1 event in last 1 year.
•
Racism and Lost Fentanyl: Inside a Bombshell Complaint Against NephronFits News•Jul 07, 2026•Nephron Pharmaceuticals
•
WhiteHawk Capital Partners Provides Credit Facility to Nephron PharmaceuticalsBusiness Wire•Jan 10, 2025•WhiteHawk Capital Partners, Nephron Pharmaceuticals
•
Sharps Technology receives $30M purchase order for prefillable copolymer syringes to be manufactured at SC facilitySeeking Alpha•Jun 13, 2024•Sharps Technology, Nephron Pharmaceuticals
•
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC FacilityBenzinga•Jun 13, 2024•Sharps Technology, Nephron Pharmaceuticals
•
Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow DepositGlobeNewswire•Jun 05, 2024•Sharps Technology, Nephron Pharmaceuticals
•
Sharps Technology jumps on $200M sales agreement for syringes with Nephron PharmaSeeking Alpha•May 30, 2024•Nephron Pharmaceuticals, Sharps Technology
•
•
NRx and Nephron join hands to formulate ketamine for depressionPharmaceutical Technology•Nov 06, 2023•NRx, Nephron Pharmaceuticals
•
Sharps Technology Issues Letter To Shareholders Covering The Announced Asset Purchase Agreement To Acquire Injectez Prefillable Syringe Manufacturing Facility And The Associated $400 Million 10-year Purchase Agreement With Nephron PharmaceuticalsGlobeNewswire•Sep 28, 2023•Sharps Technology, Nephron Pharmaceuticals
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Nephron Pharmaceuticals
Explore our recently published companies
- Captain - Montreal based, 2021 founded, Unfunded company
- Navigo - Delhi based, 2024 founded, Unfunded company
- Skynext - Mumbai based, 2020 founded, Unfunded company
- Digital Maker - Peterhead based, 2017 founded, Unfunded company
- Byteport - San Francisco based, 1999 founded, Seed company
- Back Benchers - India based, 2024 founded, Unfunded company
